Eli Radiopharma (亦立医药)

Founded in 2024 and headquartered in Hangzhou, Eli Radiopharma develops theranostic radiopharmaceuticals that integrate molecular targeting with radionuclide technology for oncology and neurological diseases. Its pipeline spans diagnostic and therapeutic candidates, several of which have completed lead-compound discovery and in vivo/in vitro validation and are approaching IND filing; its tau-PET tracer 18F-ELI-101 received NMPA clinical-trial approval for Alzheimer's disease diagnosis in March 2026. The company has also formed research collaborations on radiopharmaceutical development with partners including United Imaging Research Institute and Atomic High-Tech.

  • Series A
  • Biotechnology
  • Diagnostics
  • Healthtech
  • Pharmaceuticals
  • Healthcare & Life Sciences

1

Round

1

Industry

5

Tags

Nov 12, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 12, 2026

    CNY 59.6M

    Series A

    Led by Huagai Capital

    • Huagai Capital
    • Hongsheng Capital (弘盛资本)
    • CSPC Guofang Pioneer Fund (石药国方先导基金)
    • Kangjun Capital
    • Delian Capital (德联资本)
    • Shenzhen Angel FOF (深天使)
    • Xinneng Venture Capital (芯能创投)
    • Berui Capital (柏睿资本)
    • InnoPinnacle Fund (信成基金)
    • Haibang Investment (海邦投资)
    • Farwing Capital (远翼投资)
    • Boyu Venture Capital (博裕创投)
    • Huaige Capital (怀格资本)
    • Longfeng Venture Capital (隆峰创投)
    • Beike Fund (贝壳基金)
    • Honghou Investment (弘厚投资)

    Article coming soon.

Pricing

Research Eli Radiopharma (亦立医药) — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Eli Radiopharma (亦立医药) is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational